WA
Consensus Narrative from 8 Analysts
MACI Arthro And NexoBrid Approvals Will Broaden Future Market Access
Key Takeaways FDA approvals and new product expansions position Vericel for sustained revenue and profit growth, with potential benefits from larger patient populations. Growing adoption of MACI and NexoBrid, along with strategic manufacturing and market expansion, signals promising future revenue and margin improvements.
View narrativeUS$65.43
FV
12.7% undervalued intrinsic discount24.79%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
18 days ago author updated this narrative